Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Int J Drug Policy. 2020 Mar 9;88:102710. doi: 10.1016/j.drugpo.2020.102710

Figure 1. Model schematics showing (A) HCV disease progression by liver disease states and (B) stratification by harm reduction interventions.

Figure 1.

PWID: People who inject drugs; OAT: Opiate agonist therapy; HCNSP: High coverage needle/syringe exchange program (receiving ≥1 sterile syringes per injection). *PWID exiting the model due to death; ∆Current PWID transitioning to former PWID model, resulting from permanent cessation.